Instructions for use and caution of ibrutinib

Ibrutinib (ibrutinib), as a targeted anti-cancer drug, has shown remarkable results in the treatment ofB-cell malignancies such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). However, as with other drugs, the use of ibrutinib comes with specific contraindications and groups of special concern.

1. Clear taboos

1. Allergy risk: If the patient has an allergic reaction to any ingredient in ibrutinib, use should be avoided. Allergy symptoms may include rash, difficulty breathing, etc., and may be life-threatening in severe cases.

2. Severely impaired liver function: Patients whose liver function reachesChild-Pugh grade C should avoid using ibrutinib, because liver dysfunction may lead to abnormal drug metabolism and increase the risk of adverse reactions.

2. Use with caution

1. Renal insufficiency: Although patients with mild to moderate renal insufficiency (CrCl greater than 25 mL/min) are not expected to be greatly affected, patients with severe renal insufficiency and dialysis should use it with caution and closely monitor drug reactions.

2. Impaired liver function: When used in patients with mild or moderate hepatic impairment (Child-Pugh A and B), it is recommended to reduce the recommended dose and increase the frequency of adverse reaction monitoring.

3. Chronic graft-versus-host disease: Patients with abnormally elevated total bilirubin levels, especially those with total bilirubin levels exceeding 3 times the upper limit of normal should be used with caution. If it is of nonhepatic origin or due to Gilbert's syndrome, special evaluation is required. In patients with total bilirubin levels between 1.5 and 3 times, a reduction in the recommended dose is recommended.

4. Heart health problems: Since ibrutinib may have effects on the heart, such as arrhythmia and heart failure, patients with cardiac comorbidities (such as hypertension, diabetes, history of arrhythmia, etc.) should use it with caution and have their heart rhythm and cardiac function monitored regularly.

In order to ensure the effectiveness of treatment and patient safety, it is recommended that patients understand the above contraindications and cautions in detail before using ibrutinib, and make medication decisions under the guidance of a professional doctor. In addition, ibrutinib is available in domestic and foreign markets, but prices vary depending on region and version. Patients should choose cost-effective drug versions to purchase and use based on their own needs and actual conditions.